The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II study of ADT + abiraterone versus ADT + abiraterone + docetaxel in patients with low-volume metastatic hormone-sensitive prostate cancer.
 
Sarah Elizabeth Fenton
No Relationships to Disclose
 
Masha Kocherginsky
Honoraria - Bristol Myers Squibb Foundation
Patents, Royalties, Other Intellectual Property - Royalties - co-inventor on Patent 9149485, "Methods and compositions related to glucocorticoid receptor antagonists and breast cancer".
 
David James VanderWeele
Honoraria - Astellas Pharma; Myovant Sciences
Consulting or Advisory Role - Bayer; Janssen
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); Curium Pharma (Inst); Fortis (Inst); Harpoon therapeutics (Inst); Janssen Oncology (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Janssen Oncology
 
Maha H. A. Hussain
Honoraria - Academic CME; AstraZeneca; AstraZeneca; Bayer; Bayer; Clinical Care Options; Great Debates and Updates; Medscape; Merck; Novartis; Research to Practice; Targeted Oncology
Consulting or Advisory Role - AstraZeneca; Bayer; Bayer; Convergent Therapeutics; GlaxoSmithKline; GlaxoSmithKline; Janssen; Merck; Novartis; Novartis; Pfizer; Tango Therapeutics; Tempus
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
Travel, Accommodations, Expenses - Bayer